Progenix slips on mixed Q2, misses on revenue

|By:, SA News Editor

Progenix Pharmaceuticals (PGNX -1.2%) slips after reporting a mixed Q2, coming in-line on a per share basis but missing on revenue.

Royalty income was $1.2M compared to $1.6M in Q212, largely based on net sales of Relistor.

Relistor global net sales increased 2% Q/Q, but fell by 27% Y/Y.